Taken together, these results demonstrate that eIF4A is an important therapeutic target in KRAS-mutant NSCLC cells and that suppression of this eIF4F component dramatically sensitizes lung cancer cells to both KRAS G12C and MEK inhibitors. Here, MAP2K7 is linked to non-small cell lung carcinoma.